Hirotaka Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hirotaka Yan has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Daisuke Yamabe
Department of Orthopaedic Surgery, Iwate Medical University, Yahaba-cho, Shiwagun, Iwate, Japan
2 shared publications - Hideki Murakami
Department of Orthopedic Surgery, School of Medicine, Iwate Medical University, Japan
2 shared publications - Hirooki Endo
Department of Orthopedic Surgery, School of Medicine, Iwate Medical University, Japan
2 shared publications Yusuke Chiba
Department of Orthopaedic Surgery, Iwate Medical University 028-3695, Yahaba, Japan
2 shared publicationsAi Chida
Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Iwate Medical University 028-3695, Yahaba, Japan
1 shared publicationDaisuke Yamabe
Department of Orthopedic Surgery, School of Medicine, Iwate Medical University, Japan
1 shared publication
Latest Publications
- Open Access
- 22 January 2025
- Published by Wiley in Case Reports in Endocrinology
- Vol. 2025 (1) , 9514578
Successful Treatment With Evocalcet Against Familial Hypocalciuric Hypercalcemia Type 3 (FHH3) Identified by AP2S1 Gene Mutation (p.Arg15Leu)
Background: Familial hypocalciuric hypercalcemia type 3 (FHH3) is a rare hereditary disorder caused by a heterozygous AP2S1 gene mutation, characterized by hypocalciuria and hypercalcemia due to impaired intracellular signal transduction of calcium (Ca)‐sensing receptors (CaSRs). All affected patients harbored a heterozygous missense mutation at the Arg15 residue of the encoded AP2σ1. Case Presentation: A 21‐year‐old female was referred to our hospital with hypercalcemia and reduced bone mineral density (BMD) detected during a preoperative examination for scoliosis surgery. She had a developmental disorder and exhibited hypocalciuria on urinalysis. Genetic testing revealed a heterozygous AP2S1 gene mutation (p.Arg15Leu), and the patient was diagnosed with FHH3. In the present case, we investigated the effects of evocalcet, a newly approved CaSR agonist. Treatment with evocalcet gradually decreased and normalized the serum Ca level, and promoted improvements in bone metabolism, without serious adverse events. Conclusion: Evocalcet may be a promising therapeutic candidate for symptomatic FHH3.
- 22 January 2025
- Published by Wiley in Case Reports in Endocrinology
- Vol. 2025 (1) , 9514578
Open AccessSuccessful Treatment With Evocalcet Against Familial Hypocalciuric Hypercalcemia Type 3 (FHH3) Identified by AP2S1 Gene Mutation (p.Arg15Leu)
Background: Familial hypocalciuric hypercalcemia type 3 (FHH3) is a rare hereditary disorder caused by a heterozygous AP2S1 gene mutation, characterized by hypocalciuria and hypercalcemia due to impaired intracellular signal transduction of calcium (Ca)‐sensing receptors (CaSRs). All affected patients harbored a heterozygous missense mutation at the Arg15 residue of the encoded AP2σ1. Case Presentation: A 21‐year‐old female was referred to our hospital with hypercalcemia and reduced bone mineral density (BMD) detected during a preoperative examination for scoliosis surgery. She had a developmental disorder and exhibited hypocalciuria on urinalysis. Genetic testing revealed a heterozygous AP2S1 gene mutation (p.Arg15Leu), and the patient was diagnosed with FHH3. In the present case, we investigated the effects of evocalcet, a newly approved CaSR agonist. Treatment with evocalcet gradually decreased and normalized the serum Ca level, and promoted improvements in bone metabolism, without serious adverse events. Conclusion: Evocalcet may be a promising therapeutic candidate for symptomatic FHH3.
- Open Access
- 30 November 2023
- Published by Elsevier in World Neurosurgery
- Vol. 182, e463-e470
Finite Element Modeling for Biomechanical Comparisons of Multilevel Transforaminal, Posterior, and Lateral Lumbar Approaches to Interbody Fusion Augmented with Posterior Instrumentation
- 30 November 2023
- Published by Elsevier in World Neurosurgery
- Vol. 182, e463-e470
Open AccessFinite Element Modeling for Biomechanical Comparisons of Multilevel Transforaminal, Posterior, and Lateral Lumbar Approaches to Interbody Fusion Augmented with Posterior Instrumentation
- Open Access
- 16 February 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (4) , 1020
Comparison of Hybrid Posterior Fixation and Conventional Open Posterior Fixation Combined with Multilevel Lateral Lumbar Interbody Fusion for Adult Spinal Deformity
We compared radiological and clinical outcomes between multilevel lateral lumbar interbody fusion (LLIF) + hybrid posterior fixation (PF) and multilevel LLIF + conventional open PF in patients with adult spinal deformity (ASD). Patients who underwent minimally invasive surgery for ASD in a single institution between 2014 and 2018 were retrospectively reviewed. Fifty-six patients (hybrid PF, 30; open PF, 26) who underwent ASD correction surgery were enrolled between 2014 and 2018. We evaluated patients’ demographics, clinical outcomes, and radiographical parameters in each group. There was significantly less estimated blood loss in the hybrid PF group (662.8 mL vs. 1088.8 mL; p = 0.012). The CRP level 7 days after surgery was significantly lower in the hybrid PF group (2.9 mg/dL vs. 4.3 mg/dL; p = 0.035). There was no significant difference between the two groups in other demographic variables, visual analog scores for back pain and leg pain, Oswestry Disability Index, coronal Cobb angle, lumbar lordosis, pelvic tilt, pelvic incidence–lumbar lordosis mismatch, and sagittal vertical axis. There was a significantly higher percentage of major complications in the open PF group (42.3% vs. 13.3%; p = 0.039). Thus, LLIF + hybrid PF for ASD corrective surgery may be comparable to LLIF + open PF in terms of clinical and radiographic outcomes.
- 16 February 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (4) , 1020
Open AccessComparison of Hybrid Posterior Fixation and Conventional Open Posterior Fixation Combined with Multilevel Lateral Lumbar Interbody Fusion for Adult Spinal Deformity
We compared radiological and clinical outcomes between multilevel lateral lumbar interbody fusion (LLIF) + hybrid posterior fixation (PF) and multilevel LLIF + conventional open PF in patients with adult spinal deformity (ASD). Patients who underwent minimally invasive surgery for ASD in a single institution between 2014 and 2018 were retrospectively reviewed. Fifty-six patients (hybrid PF, 30; open PF, 26) who underwent ASD correction surgery were enrolled between 2014 and 2018. We evaluated patients’ demographics, clinical outcomes, and radiographical parameters in each group. There was significantly less estimated blood loss in the hybrid PF group (662.8 mL vs. 1088.8 mL; p = 0.012). The CRP level 7 days after surgery was significantly lower in the hybrid PF group (2.9 mg/dL vs. 4.3 mg/dL; p = 0.035). There was no significant difference between the two groups in other demographic variables, visual analog scores for back pain and leg pain, Oswestry Disability Index, coronal Cobb angle, lumbar lordosis, pelvic tilt, pelvic incidence–lumbar lordosis mismatch, and sagittal vertical axis. There was a significantly higher percentage of major complications in the open PF group (42.3% vs. 13.3%; p = 0.039). Thus, LLIF + hybrid PF for ASD corrective surgery may be comparable to LLIF + open PF in terms of clinical and radiographic outcomes.